Shelley Coleman Selected Research

Neoplasm Metastasis (Metastasis)

1/2022	IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
1/2019	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
6/2018	Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shelley Coleman Research Topics

Disease

4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020 - 06/2018
3	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2018
2	Neoplasms (Cancer) 01/2020 - 06/2018
1	Brain Neoplasms (Brain Tumor) 01/2022

Drug/Important Bio-Agent (IBA)

5	atezolizumabIBA 01/2022 - 06/2018
5	Bevacizumab (Avastin)FDA Link 01/2022 - 06/2018
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 01/2019
4	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 01/2019
2	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2019
2	B7-H1 AntigenIBA 01/2020 - 06/2018
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2018

Therapy/Procedure

4	Drug Therapy (Chemotherapy) 01/2022 - 06/2018
1	Immunotherapy 01/2020
1	Therapeutics 01/2020